On March 9, 2018 – Crescendo Biologics Limited (Crescendo), the drug developer of novel,
targeted T-cell engaging therapeutics, announces that James Legg, VP R&D, will be presenting at the 4th
Annual Crown Bioscience Cambridge Symposium on 15 March 2018 (Press release, Crescendo Biologics, MAR 9, 2018, View Source [SID1234525093]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 4th Annual Crown Bioscience Cambridge Symposium is being held at the Babraham Research
Campus on 15 March. This year, the symposium will focus on immuno-oncology and the future advances
in cancer treatment, with the symposium entitled ‘Perspectives on Oncology Drug Discovery: ImmunoOncology
and the Next Generation’. Discussion topics will include how to assess long term anti-tumour
immunotherapeutic efficacy, novel targets for next generation immuno-oncology agents, as well as
preclinical models for improved evaluation of immuno-therapeutics.
Title: Perspectives on Oncology Drug Discovery: Immuno-Oncology and the Next Generation
Date: 15 March 2018
Time: Whole day event
Location: The Cambridge Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT